信达生物(01801.HK)IBI310联合治疗三期临床研究完成首例患者给药
信达生物(01801.HK)公布,旗下抗CTLA-4单克隆抗体产品IBI310,联合公司与礼来制药(LLY.US)合作研发的的信迪利单抗注射液PD-1抑制剂「达伯舒」,用於治疗一线晚期肝细胞癌的第三期关键临床研究已完成首例患者入组及给药。
该研究在中国开展,用以评估IBI310联合达伯舒用於一线晚期肝细胞癌的有效性和安全性。信达生物医学科学与战略肿瘤部副总裁周辉表示,CTLA-4是一个重要的免疫抑制性受体,前期临床研究结果显示IBI310联合达伯舒具有良好的安全性和抗肿瘤活性,提示联合疗法肿瘤治疗中的潜力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.